Antimicrobial resistance: investment implications from farm to pharma

The increasing resistance of bacteria to common antibiotics is one of the most important issues since modern medicine began, yet the wider costs and benefits are not fully understood.

Read full reportAntimicrobial resistance: Investment implications from farm to pharma
12 pages4948 KB


Seema Suchak
Head of Sector Research, ESG

The cost of drug-resistant infections is potentially huge. Leading economists estimate resistance could contribute to 10 million deaths per year at a cost of $100 trillion by 2050 if no action is taken.

Yet the food and drug industries and investors do not yet factor in fully the implications and opportunities.

With a growing number of bacteria able to survive in the presence of antibiotics, it becomes increasingly difficult for doctors to cure patients with infections. Antimicrobial resistance (AMR) has been accelerated by the misuse and overuse of antibiotics in humans and animals.

For instance, globally, 480,000 people develop multi-drug resistant tuberculosis each year, and in 2016, news broke that bacteria were developing resistance to colistin, a ‘last-resort’ antibiotic.

AMR could fundamentally undermine the value of industries tied to conventional antimicrobials as lawmakers crack down on their excessive use and availability. Here, we briefly look at the implications for the healthcare and food industries and highlight potential risks and opportunities.

Sector implications: healthcare industry

While the healthcare sector has not borne the blame for antibiotic resistance, this sector is the supplier of antibiotics for both human and animal use, and ultimately will face restrictions in how rapidly this product area can grow.

Even though access to antibiotics is growing in developing markets, indicating higher volumes, we believe this growth will be restricted, and the costs heavily controlled.

We find that incumbent manufacturers of antibiotics – particularly those that supply the farming industry – will face the biggest obstacles.

On the opportunity side, innovative drug companies could reap imminent financial rewards for inventing new classes of antibiotics - already scientifically challenging - but will likely face stricter marketing restrictions.

We see the greatest opportunities for companies providing either alternatives to antimicrobials (such as vaccines and probiotics) or peripheral services (such as diagnostic testing for infections, and cleaning services - given the role hygiene plays in spreading infection).


Sector implications: food industry

A large body of academic research highlights the farming and food industries’ roles in the AMR challenge, the increased regulatory pressure and heightened scrutiny from consumers will have an impact on company policy.

Those most likely to be affected include food producers that are reliant on antibiotics to control infection, as they could face additional costs to upgrade farming practices.

Companies providing additives to animal feed will be well placed to benefit however, as they take the opportunity to innovate and expand nutrients to reduce the reliance on antibiotics.

Retailers and restaurants are also being affected by rising consumer awareness and many are already strengthening supply chain policies restricting the use of antibiotics.

How Schroders is engaging on antibiotic stewardship

Given the substantial cross-industry investment impacts we have identified, we have sought to understand how companies are approaching and managing AMR risks and opportunities, and encouraging further data disclosure that will enable us to value the impacts in our models. This is vital: the resistance threat is not yet on corporate risk radars for 70% of the 10 companies with the largest US antibiotic sales.

Our engagement questions for healthcare companies centre on:

  • Product areas affected by the AMR trend
  • Sales, marketing and pricing disruptions
  • Approach to R&D
  • In-house knowledge of the latest policy developments
  • Impact of the O’Neill review on risk discussions
  • Assessment of the collateral impact of AMR on demand for other therapies, devices or treatments which are dependent on antibiotics

We have also supported collaborative engagement initiatives aimed at food companies in the antibiotic supply chain, led by non-profit programme Business Benchmark on Farm Animal Welfare (BBFAW).

Resolutions filed by shareholders on AMR have also started to creep into food company AGM ballots this year. The resolutions request timeframes be set on removing non-therapeutic use of antibiotics in meat supply chains.

We supported the resolution filed at Sanderson Farms but voted against at McDonald’s given the company is already committed to phasing out antibiotics.

Read full reportAntimicrobial resistance: Investment implications from farm to pharma
12 pages4948 KB

Subscribe to our Insights

Visit our preference center, where you can choose which Schroders Insights you would like to receive

The views and opinions contained herein are those of Schroders’ investment teams and/or Economics Group, and do not necessarily represent Schroder Investment Management North America Inc.’s house views. These views are subject to change. This information is intended to be for information purposes only and it is not intended as promotional material in any respect.


Seema Suchak
Head of Sector Research, ESG


Please consider a fund's investment objectives, risks, charges and expenses carefully before investing. The Schroder mutual funds (the “Funds”) are distributed by The Hartford Funds, a member of FINRA. To obtain product risk and other information on any Schroders Fund, please click the following link. Read the prospectus carefully before investing. To obtain any further information call your financial advisor or call The Hartford Funds at 1-800-456-7526 for Individual Investors.  The Hartford Funds is not an affiliate of Schroders plc.

Schroder Investment Management North America Inc. (“SIMNA”) is an SEC registered investment adviser, CRD Number 105820, providing asset management products and services to clients in the US and registered as a Portfolio Manager with the securities regulatory authorities in Canada.  Schroder Fund Advisors LLC (“SFA”) is a wholly-owned subsidiary of SIMNA Inc. and is registered as a limited purpose broker-dealer with FINRA and as an Exempt Market Dealer with the securities regulatory authorities in Canada.  SFA markets certain investment vehicles for which other Schroders entities are investment advisers.

For illustrative purposes only and does not constitute a recommendation to invest in the above-mentioned security/sector/country.

Schroders Capital is the private markets investment division of Schroders plc. Schroders Capital Management (US) Inc. (‘Schroders Capital US’) is registered as an investment adviser with the US Securities and Exchange Commission (SEC).It provides asset management products and services to clients in the United States and Canada.For more information, visit

SIMNA, SFA and Schroders Capital are wholly owned subsidiaries of Schroders plc.